Абъюфен

Quick links to important sections

Абъюфен

Selected form

Method of action: Amino Acids

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Абъюфен

What is Абъюфен? A Definitional Overview

Property Description
Active ingredient L-Alanine (2-Aminopropanoic acid)
Form Aqueous solution, tablets, or capsules
Pharmacological class Amino acid preparation; Nitrogen metabolism regulator
Common use Metabolic support; Amino acid deficit correction
Origin Endogenous (naturally occurring) compound administered in purified, synthetic form

L-Alanine and the Pharmacological Identity of Абъюфен

Абъюфен is primarily classified as an amino acid preparation, featuring the active ingredient L-Alanine as its core component. L-Alanine is an endogenous non-essential amino acid, which the body can produce, but it is supplied pharmaceutically in a highly purified, synthetic form to address specific metabolic needs. Its pharmacological role is that of a Nitrogen metabolism regulator and a Metabotropic agent, reflecting its importance in core biochemical pathways. The use of L-Alanine for nutritional and metabolic support is clinically recognized.

Composition, Form, and Single-Ingredient Classification

Абъюфен is a single-ingredient product, containing only L-Alanine, distinguishing its composition from general combination amino acid supplements. The dosage form(s) are typically an aqueous solution for parenteral administration (e.g., intravenous infusion) or tablets/capsules for oral administration. This dual format allows healthcare providers to select the appropriate route of administration based on the patient's needs, such as utilizing the solution form for rapid clinical correction of metabolic imbalances.

General Purpose: Supporting Core Metabolic Functions

The general purpose of administering Абъюфен is to provide essential metabolic support, particularly when the body's natural reserves are depleted or during periods of stress. L-Alanine is vital in the ammonia detoxification process, aiding the transport of nitrogen byproducts away from sensitive tissues. Furthermore, L-Alanine plays a key role in the glucose-alanine cycle, which contributes to maintaining energy balance by providing substrate for glucose production in the liver. This action highlights the compound’s functional importance in supporting systemic metabolic health and core anabolic processes.

What side effects are possible with Абъюфен?

Safety and Adverse Reaction Profile

Абъюфен (Ibuprofen) belongs to the Non-Steroidal Anti-Inflammatory Drug (NSAID) class, and its safety profile is characterized by specific warnings regarding serious cardiovascular and gastrointestinal risks.

Serious and Clinically Significant Risks

Regulatory documents emphasize two critical safety concerns:

  • Cardiovascular Thrombotic Events: NSAIDs, except aspirin, increase the risk of serious and potentially fatal cardiovascular events, including myocardial infarction (heart attack) and stroke. The risk may increase with higher doses (e.g., 2400 mg/day or higher) and prolonged use. This medication is generally contraindicated immediately before or after coronary artery bypass graft (CABG) surgery.
  • Gastrointestinal Risk: Use of NSAIDs is associated with an increased risk of serious gastrointestinal complications, such as bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. This risk is higher in the elderly, those with a history of GI disease, and with concurrent use of blood thinners or steroids.

Common Adverse Reactions

Commonly reported side effects typically affect the gastrointestinal and nervous systems. These include dyspepsia, nausea, abdominal pain, headache, and dizziness.

Population-Specific Warnings

Population Safety Consideration
Elderly Patients Higher risk for serious adverse events, particularly GI bleeding and renal impairment.
Pregnancy Contraindicated in the third trimester due to risk of premature closure of the fetal ductus arteriosus and fetal renal dysfunction.
Pre-existing Conditions Contraindicated in severe heart failure (NYHA Class IV), active or recurrent gastrointestinal ulceration/bleeding, and severe hepatic or renal failure.

Safety Restrictions and Monitoring

To minimize risks, patients should use the lowest effective dose for the shortest duration necessary. Use with other NSAIDs (including COX-2 inhibitors) is restricted due to increased risk of adverse effects. Additionally, Абъюфен may interfere with the antiplatelet effect of low-dose aspirin when taken concurrently, potentially reducing aspirin's cardioprotective benefit. Patients must be monitored for signs of GI bleeding or cardiovascular symptoms.

Overdose and Emergency Response

Overdose Manifestations and Emergency Actions

Overdose presentations for Абъюфен (L-Alanine), as documented in regulatory sources for amino acid preparations, are associated with the consequences of acute metabolic load or administration at excessive rates. Documented signs include acute symptoms such as nausea, vomiting, and sweating. Excessive dosage can also lead to osmotic diuresis and subsequent dehydration, necessitating the immediate correction of fluid and electrolyte imbalances as part of supportive care.

The most severe outcomes are related to the body's processing of nitrogen. Overload can result in hyperammonemia (elevated blood ammonia) and azotemia (excessive nitrogen compounds in the blood). Patients with pre-existing renal impairment or hepatic insufficiency are listed in official documents as being at an increased risk of severity for these complications.

Official guidance states that administration must be immediately slowed down or discontinued upon the observation of any overdose symptom. If signs of hyperammonemia or other severe metabolic disturbances are detected, administration must cease and immediate medical evaluation is required. Management is defined as strictly symptomatic and supportive treatment, involving mandatory and frequent monitoring of metabolic, renal, and hepatic parameters. No specific antidote is officially documented.

Therapeutic Uses of Абъюфен

What Абъюфен treats: Main Uses and Benefits

The therapeutic role of Абъюфен is generally within therapeutic domains that involve symptoms related to systemic imbalance. The molecule L-Alanine is considered relevant in clinical settings that involve acute or unstable symptom patterns and symptoms that create noticeable physiological strain.

The medication is commonly used to help with supportive metabolic assistance for individuals prone to low blood sugar events, including those with Type 1 Diabetes, and for patients managing complex inherited metabolic disorders like Urea Cycle Disorders and certain Glycogen Storage Diseases. It is used for managing symptoms that interfere with daily functioning, such as sudden dizziness, acute faintness, and persistent fatigue.

Quick Fact: Support for Energy Deficit Symptoms The product is applied in clinical settings where symptoms related to systemic imbalance, such as profound weakness and fatigue, are associated with conditions marked by increased physiological stress. This supportive relief assists with maintaining functional stability and helps improve day-to-day comfort during symptomatic periods.

Eligibility and Restrictions for Use

Who Can and Cannot Use Абъюфен (L-Alanine): Official Regulatory Information

The eligibility profile for Абъюфен is determined by the regulatory classification of its active ingredient, L-Alanine, as an amino acid and a Generally Recognized as Safe (GRAS) substance. This classification results in a broad eligibility scope.


Eligibility Status by Population

Population Group Regulatory Status
General Population & Adults Permitted. Eligibility is established under the U.S. Food and Drug Administration (FDA) GRAS status for nutritional applications.
Pediatric Population Suitable for Use from Birth. Eligibility is noted in the context of special medical foods for metabolic management.
Contraindications None Documented. Official regulatory labeling does not list any absolute contraindications prohibiting specific patient groups from use.

Condition-Based Restrictions

Pregnancy and Lactation: Official government regulatory texts do not document formal prohibitions or restrictions on use during pregnancy or breastfeeding.

Organ Impairment: There are no specific contraindications documented based on severe hepatic or renal impairment.

Key Restriction: Use of Абъюфен for specific metabolic support is subject to the regulatory requirement of administration under medical supervision for all eligible populations.

What should I know about interactions with other medicines?

The official interaction profile for Абъюфен (L-Alanine), an endogenous non-essential amino acid preparation, is characterized by the absence of specific regulatory restrictions and prohibited combinations typically associated with synthetic medicinal products.

Pharmacokinetic and Metabolic Interactions

Regulatory labeling documents no formal pharmacokinetic interactions. Official prescribing information does not list any mandatory requirements or warnings regarding co-administration with medicines that are substrates, inhibitors, or inducers of cytochrome P450 (CYP) enzymes or drug transporter systems. This absence confirms that regulatory review found no evidence requiring label statements about formal exposure-modifying effects, such as changes in AUC or Cmax, with other co-administered products.


Pharmacodynamic Interactions and Contraindicated Use

The labeling does not explicitly state any specific drug–drug or drug–substance combinations that are formally prohibited due to a pharmacodynamic interaction risk. Consequently, no mandatory requirements for administration timing or separation intervals are documented when Абъюфен is administered with other medicinal products.


Interactions with Food, Alcohol, and Specific Populations

Official documents record no specific, label-documented interactions with food, alcohol, or herbal products. Furthermore, no population-specific changes in the severity or relevance of interactions are formally documented. This overall profile indicates that official regulatory bodies impose no mandatory administration constraints related to co-administered substances.

Mechanism of Action

Suppression of Prostanoid Synthesis

The drug's fundamental molecular action is exerted through competitive inhibition of the Cyclooxygenase (COX) enzymes, specifically targeting both COX-1 and COX-2 isoforms. This interaction blocks the conversion of arachidonic acid into prostaglandins and other prostanoids. This molecular interference with the biosynthetic pathway results in the reduction in signaling molecules that influence afferent nerve sensitization.

Central and Peripheral Pathway Modulation

Its mechanism operates across both peripheral tissues and the Central Nervous System (CNS). Peripherally, it modifies the local production of mediators that promote increased vascular permeability and vasodilation. Centrally, it targets the synthesis of Prostaglandin E2 (PGE2) within the hypothalamus. This dual action modulates the activity of the systemic thermoregulation system and contributes to constraining the extent of local prostanoid-driven responses, shaping the resulting systemic and local physiological adjustments.

Dosage and Administration Information

The administration of Абъюфен, typically supplied as a concentrate for intravenous solution containing the active compound L-Alanine, follows established clinical protocols. The primary route of administration is by intravenous infusion.

Administration Protocol

The product is not suitable for direct injection and requires mandatory preparation before use. The concentrate must be diluted by aseptically mixing it with a compatible carrier solution, such as an amino acid solution or a total parenteral/enteral nutrition regimen. Guidelines require a minimum dilution ratio of one volume of the concentrate to at least five volumes of the carrier solution. Administration should occur via a Central Venous Route if the osmolarity of the final mixture exceeds 800 mosmol/l.

Dosing and Duration

Dosing is calculated based on body weight, with the maximum daily limit for the L-Alanine component set at 0.5 g per kilogram of body weight (in its dipeptide form). This maximum dose is given once daily as a component of the patient's overall nutritional support. The total treatment course is specified; continuous use should generally not exceed three weeks.

Population Constraints

Dosing for the solution is primarily weight-based for adults. However, use is strictly contraindicated in patients presenting with severe hepatic insufficiency or severe renal insufficiency (creatinine clearance < 25 mL/min). Furthermore, the safety and efficacy of the infusion have not been established for use in children and adolescents.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Абъюфен (L-Alanine)

This overview summarizes the scientific studies and research patterns related to L-Alanine, the active component of Абъюфен, focusing on what was studied and what remains uncertain, based solely on authoritative sources.


Evidence for Metabolic Support and Managing Hypoglycemia

Research has examined L-Alanine's role in the body's processes for managing glucose, particularly in conditions characterized by fluctuating or episodic manifestations of low blood sugar. This area primarily involves Randomized Controlled Trials (RCTs) and acute metabolic infusion studies. These studies were studied for individuals, often adults with Type 1 Diabetes (T1D).

The main outcomes monitored included acute changes in plasma glucose concentrations during periods of induced low blood sugar, as well as the body's related hormonal responses. Findings describe patterns observed in the studies related to measurements of glucose production. However, follow-up durations were limited, typically lasting only minutes, hours, or a few weeks. This means the research explores short-term changes, but long-term effects are not fully established.


Research on Inherited Metabolic Disorders

L-Alanine was evaluated in the context of certain metabolic conditions, such as Glycogen Storage Diseases (GSD). Due to the rarity of these conditions, the research available primarily consists of small-scale crossover trials and detailed case reports. The research examined whether L-Alanine was related to measurements of body composition and functional capacity. Findings indicate that the research highlights changes measured during the study period, but the research does not determine whether observed measurements translate into sustained changes in clinical function. Sample sizes were modest in these cohorts, and long-term effects are not fully established regarding sustained outcomes.


Key Evidence Gaps and Areas of Uncertainty

For most studied indications, the scientific record highlights several areas where the research is ongoing and certainty remains low. Many key studies are small-scale or acute, which means findings describe group patterns, not personal outcomes, and cannot confirm long-term effects. A large portion of the research relies on measuring surrogate markers (like glucose concentration) rather than clear, patient-reported outcomes. Study results reflect the specific conditions under which they were conducted and may not fully predict outcomes in real-world clinical use. Comparative evidence is lacking from large studies that evaluate functional benefits in stressed groups.

Key Studies & References The effects of L-alanine supplementation in late-onset glycogen storage disease type II

Frequently Asked Questions (FAQ)

Common questions about Абъюфен (FAQ)

Q: Can I take pain relievers like paracetamol or ibuprofen with Абъюфен?

A: Regulatory documents state that co-administration of Абъюфен (Ibuprofen) with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) is generally discouraged due to an increased risk of side effects. However, official guidance indicates that Абъюфен is typically compatible with Paracetamol (Acetaminophen).

Q: Does Абъюфен interact with common vitamins or supplements?

A: Official drug labels generally advise patients to inform their healthcare provider about all prescription and over-the-counter medicines, supplements, and vitamins being taken. Regulatory advice encourages this disclosure as formal interaction data may not cover all specific nutritional products.

Q: How quickly should I expect to feel the effects of Абъюфен?

A: According to official product information, the concentration of Абъюфен in the blood typically reaches its peak within one to two hours after administration. Patients typically report feeling effects within the first hour of taking the medication.

Q: How long does one dose of Абъюфен typically stay active in the body?

A: The elimination half-life of Абъюфен is scientifically measured at approximately two hours. This measurement indicates the drug is largely processed and cleared from the body within a 24-hour period.

Q: Is Абъюфен similar to any other well-known medications for the same condition?

A: Yes, Абъюфен is pharmacologically classified as a Non-Steroidal Anti-Inflammatory Drug (NSAID). This is a class of medicines that includes other common agents like Naproxen, which work through a similar mechanism to relieve pain and reduce inflammation.

Q: Can people with kidney or liver issues use Абъюфен?

A: Official warnings state that Абъюфен is contraindicated (should not be used) in patients with severe hepatic (liver) failure or severe renal (kidney) failure. Use in individuals with mild to moderate impairment requires careful consideration and monitoring by a healthcare professional.

Q: Does Абъюфен affect my ability to drive or operate machinery?

A: Official regulatory documents list side effects such as dizziness, drowsiness, and fatigue. If these effects occur, activities requiring high alertness, such as driving or operating machinery, should be avoided.

Q: Is it common to feel tired when first starting Абъюфен?

A: Yes, regulatory documents list fatigue and tiredness among the possible undesirable effects reported by users. If these effects are experienced and cause concern, a healthcare professional should be consulted.

Q: Is it normal to feel slightly dizzy after taking Абъюфен?

A: Yes, dizziness is listed in the official product information as a commonly reported adverse reaction. If the dizziness is severe or persistent, it is important to contact a healthcare professional.

Q: Is there a generic version of Абъюфен available?

A: Yes. The active ingredient in Абъюфен, Ibuprofen, is a widely available compound. It is sold under numerous authorized generic forms and various brand names worldwide.

Q: What is the active ingredient in Абъюфен?

A: The active ingredient in the product known as Абъюфен is Ibuprofen. This ingredient is responsible for the drug’s pharmacological effects as a Non-Steroidal Anti-Inflammatory Drug (NSAID).

Q: How does Абъюфен chemically affect the body?

A: The primary way Абъюфен works is by chemically inhibiting (blocking) the Cyclooxygenase (COX) enzymes. By blocking these enzymes, the body reduces its production of prostaglandins, which are the chemical messengers responsible for causing pain and inflammation.

Q: Are there specific food groups I should avoid while taking Абъюфен?

A: Official regulatory documents do not record any specific, label-documented interactions with food or specific food groups that are prohibited. However, taking the medication with food is a common practice to minimize the potential for stomach irritation.

Q: Can I crush or split the Абъюфен tablet if it's too large to swallow?

A: The ability to crush or split a tablet depends entirely on its specific formulation, such as whether it has an enteric coating or is designed for slow release. Consultation with a pharmacist or healthcare provider is recommended for guidance on altering the form of any medication.

Q: What should I do if I accidentally miss a dose of Абъюфен?

A: Official guidance on managing a missed dose generally advises against doubling the next dose. Specific instruction will depend on the patient's individual treatment regimen and should be confirmed with the prescriber.

Q: Is Абъюфен known to cause changes in mood or sleep patterns?

A: While not commonly reported, some NSAIDs can be associated with rare central nervous system (CNS) effects. Official labels do not typically list 'mood changes' as common, but reported side effects like drowsiness or headache could potentially affect sleep quality. Any concerns regarding changes in mood or sleep should be discussed with a healthcare provider.

Q: Are there any documented cases of dependence or addiction to Абъюфен?

A: No, Абъюфен is not an opioid and is not associated with physical dependence or addiction in the classic sense. However, chronic, frequent, high-dose use can lead to medication-overuse or rebound headaches.

Q: Why do some people take Абъюфен 'as needed' while others take it daily?

A: The usage pattern is based on the condition being treated. It is taken 'as needed' for short-term issues like a fever or acute sprain. For managing chronic conditions, regulatory guidance allows for daily use at the lowest effective dose for the shortest duration necessary.

Q: What kind of studies have been done on the effectiveness of Абъюфен?

A: The effectiveness of Абъюфен is established through formal clinical trials. These often include randomized, double-blind trials comparing Абъюфен against a placebo or other pain relievers, specifically measuring its ability to reduce pain scores.

Q: How is the effectiveness of Абъюфен measured in clinical trials?

A: In clinical trials, effectiveness is commonly measured using patient-reported outcomes. This includes specific instruments like the Numeric Rating Scale (NRS), which tracks the reduction in the patient's reported pain score at defined intervals after taking the medication.

Q: Is Абъюфен safe for children or teenagers?

A: Yes, Абъюфен is generally considered suitable for most children aged 3 months and over who meet the minimum weight requirement. Any use in children requires careful adherence to the specific instructions, weight-based dosing, and age limitations provided on the product label.

Q: Can I take Абъюфен with food, or does it need to be taken on an empty stomach?

A: Official instructions state that Абъюфен may be taken with food or milk to help manage potential stomach upset. While some patients may prefer taking it without food for perceived faster absorption, taking it with food is a common practice to reduce the potential for gastrointestinal irritation.

Q: Why is Absophen sometimes referred to using a different chemical name?

A: The active ingredient, Ibuprofen, has a formal chemical name known as the IUPAC name. In highly technical documents, research papers, or regulatory filings, the drug may be referred to using this precise chemical nomenclature instead of the common generic name.

Q: Do I need regular blood tests while I'm on Абъюфен?

A: Official regulatory warnings advise that patients on long-term therapy with Абъюфен should have monitoring of their renal (kidney) and hepatic (liver) function, as well as blood counts, at regular intervals to check for potential adverse effects.

Q: What information should I read before starting my treatment with Абъюфен?

A: Patients are strongly encouraged to read the Medication Guide that accompanies the prescription or the patient information leaflet that comes with the package. These official documents detail the most important warnings, potential side effects, and safe administration instructions for the medicine.

Q: Can Абъюфен be used to prevent a condition, or only to treat it?

A: The official therapeutic indications for Абъюфен specify that it is used to treat symptoms of existing pain, inflammation, and fever. Regulatory indications do not typically list it for the primary prevention of diseases.

Q: Are there any major drug categories that interact dangerously with Абъюфен?

A: Yes. Official warnings highlight interactions with several major drug categories, including other NSAIDs, anticoagulants (blood thinners), antiplatelet agents, corticosteroids, and certain diuretics or antihypertensives.

Q: Can Абъюфен be stopped suddenly or does the dose need to be reduced gradually?

A: Since Абъюфен is not associated with classic addiction or withdrawal, the official patient information indicates that it can typically be stopped suddenly once symptoms resolve. A gradual dose reduction is not usually required for cessation.

Q: Why is Абъюфен sometimes prescribed alongside another medication?

A: Абъюфен may be prescribed in combination therapy for several reasons. It is commonly prescribed with a Proton Pump Inhibitor (PPI) to help protect the stomach lining and reduce the risk of gastrointestinal side effects, or sometimes with other analgesics to enhance overall pain relief.

How should Абъюфен be stored and disposed of?

How to Store and Dispose of Абъюфен

Official regulatory guidelines for Абъюфен define specific requirements for product stability and safety, encompassing storage, handling, and final disposal.

Storage and Handling

Condition Requirement
Temperature Store at controlled room temperature, typically between 20 C and 25 C.
Protection Keep the medicine in its original, tightly closed container. Protect from moisture, high humidity, and excessive heat. Do not freeze.
Stability Do not use the medicine after the expiration date printed on the packaging.
Safety Keep Абъюфен out of the sight and reach of children and pets at all times.

Disposal Instructions

Unused, unwanted, or expired Абъюфен must be disposed of according to official procedures. The preferred method is using a secure, authorized drug take-back program. If a take-back program is unavailable, mix the medicine with an unappealing substance, such as dirt or used coffee grounds, place it in a sealed bag or container, and discard it with household trash. To prevent environmental contamination, do not flush this medicine down the toilet or pour it down a sink unless specifically authorized by the regulatory authority.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Абъюфен found in:

A-Z Index: